Management of Left Ventricular Hypertrophy Detected on ECG

Diagnostic Approach

The European Heart Journal recommends determining if Left Ventricular Hypertrophy (LVH) is due to hypertension or hypertrophic cardiomyopathy (HCM) by evaluating family history, ECG pattern, maximum LV wall thickness, and response to blood pressure control 1

The American College of Cardiology recommends first-line agents for LVH regression, including ARBs, particularly losartan, due to superior efficacy in reducing left ventricular mass and myocardial fibrosis 2
ACE inhibitors are equally effective as ARBs in reducing LVH when ARBs are not tolerated, according to the American Heart Association 2, 3
Thiazide or thiazide-like diuretics can be added for blood pressure control and have shown efficacy in LVH regression, as recommended by the American College of Cardiology 4, 3

The American Heart Association recommends a target blood pressure of <130/80 mmHg for most patients with LVH 3

The European Heart Journal recommends regular aerobic exercise, body weight control, and dietary modifications, including increased consumption of vegetables, fresh fruits, fish, nuts, and unsaturated fatty acids, to help manage LVH 5
Sodium restriction is also recommended, as suggested by the American College of Cardiology 3

The American Heart Association recommends avoiding non-dihydropyridine calcium channel blockers, alpha-blockers, potent direct-acting vasodilators, and nonsteroidal anti-inflammatory agents in patients with LVH due to potential negative effects 4, 3

The American College of Cardiology recommends different management strategies for LVH due to hypertrophic cardiomyopathy, including non-vasodilating beta-blockers, verapamil or diltiazem, and disopyramide, as first-line therapy 2

The American College of Cardiology recommends CMR imaging for diagnostic clarification if echocardiography is inconclusive, and for patients with LVH where alternative diagnoses are suspected, such as infiltrative/storage disease or athlete's heart 6

The American Heart Association, as published in Circulation, advises avoiding non-dihydropyridine calcium channel blockers, alpha-blockers, potent direct-acting vasodilators like minoxidil, and nonsteroidal anti-inflammatory agents in patients with LVH due to their potential to exacerbate the condition or interfere with its management 7
For patients with HF with preserved LVEF (HFpEF), the American Heart Association recommends beta-blockers, ACE inhibitors, and ARBs to control blood pressure, with ARBs potentially decreasing hospitalizations 7

The American Heart Association suggests sodium restriction as part of dietary modifications to manage LVH, alongside increased consumption of vegetables, fresh fruits, fish, nuts, and unsaturated fatty acids 7